Skip to main content

Table 2 Frequencies of APOBEC3G gene polymorphisms (cases vs. controls)

From: HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso

      HIV (+) versus HIV(−)/HBV(−) HBV(+) versus HIV(−)/HBV(−) HIV(+)/HBV(+) versus HIV(−)/HBV(−)
Polymorphisms HIV(+) HBV(+) HIV(+)/HBV(+) HIV(−)/HBV(−) OR 95 % CI p-Value OR 95 % CI p-Value OR 95 % CI p-Value
  (n = 35) (n = 65) (n = 85) (n = 239)          
rs6001417              
 CC, n (%) 10 (28.57) 15 (0.23) 26 (30.59) 64 (0.27) 1.09 0.5–2.4 0.84 0.82 0.43–1.56 0.63 1.2 0.7–2.07 0.57
 CG, n (%) 17 (48.57) 40 (0.61) 48 (56.47) 114 (0.48) 1.03 0.51–2.1 1 1.75 1.01–3.07 0.05 1.47 0.89–2.42 0.13
 GG, n (%) 8 (22.86) 10 (0.15) 11 (12.94) 61 (0.25) 0.415 0.37–2 0.84 0.415 0.37–2 0.84 0.415 0.207–0.83 0.02
 G vs C, n (%) 33 (0.94) 60 (.92) 35 (0.41) 236 (0.99) 0.9 0.55–1.51 0.8 0.82 0.55–1.2 0.32 0.759 0.5–1.06 0.06
 HWE 0.74 0.16 0.20 0.38
rs8177832              
 AA. n (%) 10 (28.57) 15 (0.23) 27 (31.76) 69 (28.87) 0.98 0.45–2.16 1 0.74 0.39–1.4 0.43 1.15 0.67–1.96 0.7
 AG. n (%) 18 (0.51) 40 (0.61) 45 (52.94) 111 (0.46) 1.22 0.60–2.48 0.59 1.84 1.05–3.23 0.04 1.34 0.82–2.2 0.26
 GG. n (%) 7(0.2) 10 (0.15) 13 (15.30) 59 (0.25) 0.76 0.32–1.84 0.67 0.55 0.26–1.15 0.13 0.53 0.28–1.02 0.07
 G vs A. n (%) 32 (0.91) 60 (0.92) 36 (42.35) 229 (0.96) 0.9 0.55–1.51 0.8 0.82 0.55–1.2 0.32 0.77 0.54–1.09 0.15
 HWE 0.98 0.16 0.59 0.21
rs35228531              
 CC. n (%) 18 (0.51) 18 (0.51) 40 (47.05) 84 (35.15) 1.95 0.96–4 0.09 1.15 0.65–2.03 0.66 1.64 0.99–2.71 0.07
 CT. n (%) 15 (0.43) 15 (0.43) 38 (44.70) 113 (0.47) 0.84 0.4–1.71 0.17 0.95 0.55–1.65 0.89 0.93 0.57–1.53 0.80
 TT. n (%) 2 (0.06) 2 (0.06) 7 (8.25) 42 (0.17) 0.28 0.06–1.23 0.09 0.85 0.40–1.80 0.85 0.4 0.17–0.9 0.04
 T vs C. n (%) 19 (0.54) 19 (0.54) 25 (29.88) 197 (0.82) 0.53 0.3–0.93 0.03 0.89 0.6–1.33 0.615 0.61 0.42–0.90 0.01
 HWE 0.88 0.98 0.86 0.55
  1. HWE Hardy-Weinberg equilibrium, OR odds ratio, CI confidence interval. Significant p-Values are in bold